Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells ...
In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...
Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...
ProImmune Ltd, a global leader in life science reagents and services, today announced the launch of its new ProVE® SL Self-Loading MHC Class I Monomers. The novel reagents for antigen-specific CD8+ T ...
BACKGROUND: The entrance of naive T cells into lymph nodes (LNs) is a crucial step for induction of heart transplant acceptance under costimulatory blockade. Specialized blood vessels within the LN ...
A new AI tool that models how variations in peptides change T cell receptor binding could help design immunotherapies with fewer off-target effects. Protein complexes that adorn the surface of T cells ...
CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...
Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results